@article{TCR16582,
author = {Bryan D. Choi and William T. Curry},
title = {IDH mutational status and the immune system in gliomas: a tale of two tumors?},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 7},
year = {2017},
keywords = {},
abstract = {Gliomas are the most common type of primary brain tumor and include glioblastoma (GBM), which is the most lethal form of the disease, and remains a significant, unmet clinical need (1). Contrary to conventional notions of central nervous system immune-privilege, there is indeed extensive cross-talk between the immune system and tumors in the brain. Several successful immune therapies are either in development or have received recent approval from the Food and Drug Administration across a broad array of cancers (Table 1). However, the results for immune therapy against solid tumors in the brain have been less dramatic to date.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/16582}
}